Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Parmiani

Showing results (291-300 of 301) with videos related to

Pageof 31
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|August 1, 1998
Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killingL Rivoltini, M Radrizzani, P Accornero, et al.
The Journal of Experimental Medicine|January 1, 1995
Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytesC Castelli, W J Storkus, M J Maeurer, et al.
Gene Therapy|February 16, 2000
Type I consensus interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: implications for new therapeutic strategies with IFN-alphaM Mecchia, P Matarrese, W Malorni, et al.
Critical Reviews in Immunology|January 7, 1998
Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivityL Rivoltini, D J Loftus, P Squarcina, et al.
Cancer Gene Therapy|January 23, 1999
Gene transfer into human dendritic antigen-presenting cells by vaccinia virus and adenovirus vectorsM Di Nicola, S Siena, M Bregni, et al.
British Journal of Cancer|September 15, 2001
CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutationG Della Torre, B Pasini, S Frigerio, et al.
Cancer Immunology, Immunotherapy : CII|June 1, 1997
Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerabilityF Belli, F Arienti, J Sulé-Suso, et al.
Human Gene Therapy|December 28, 1999
Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cellsF Arienti, F Belli, F Napolitano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2013
Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanomaM Maio, R Danielli, V Chiarion-Sileni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 25, 2014
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II studyA M Di Giacomo, P A Ascierto, P Queirolo, et al.
Pageof 31

Showing results (291-300 of 301) with videos related to

Sort By:
Pageof 31
Journal of Immunology (Baltimore, Md. : 1950)|August 1, 1998
Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killingL Rivoltini, M Radrizzani, P Accornero, et al.
The Journal of Experimental Medicine|January 1, 1995
Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytesC Castelli, W J Storkus, M J Maeurer, et al.
Gene Therapy|February 16, 2000
Type I consensus interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: implications for new therapeutic strategies with IFN-alphaM Mecchia, P Matarrese, W Malorni, et al.
Critical Reviews in Immunology|January 7, 1998
Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivityL Rivoltini, D J Loftus, P Squarcina, et al.
Cancer Gene Therapy|January 23, 1999
Gene transfer into human dendritic antigen-presenting cells by vaccinia virus and adenovirus vectorsM Di Nicola, S Siena, M Bregni, et al.
British Journal of Cancer|September 15, 2001
CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutationG Della Torre, B Pasini, S Frigerio, et al.
Cancer Immunology, Immunotherapy : CII|June 1, 1997
Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerabilityF Belli, F Arienti, J Sulé-Suso, et al.
Human Gene Therapy|December 28, 1999
Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cellsF Arienti, F Belli, F Napolitano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2013
Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanomaM Maio, R Danielli, V Chiarion-Sileni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 25, 2014
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II studyA M Di Giacomo, P A Ascierto, P Queirolo, et al.
Pageof 31